A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
NCT00220363
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Overactive Bladder Syndrome
Interventions
DRUG:
SPM 907
Sponsor
Pfizer